Federated Hermes Inc. Increases Holdings in Moderna, Inc. $MRNA

Federated Hermes Inc. lifted its holdings in Moderna, Inc. (NASDAQ:MRNA) by 364.5% in the second quarter, Holdings Channel reports. The fund owned 2,869,271 shares of the company’s stock after purchasing an additional 2,251,497 shares during the quarter. Federated Hermes Inc.’s holdings in Moderna were worth $79,163,000 at the end of the most recent quarter.

Other large investors also recently added to or reduced their stakes in the company. Cetera Investment Advisers lifted its stake in shares of Moderna by 20.7% in the 1st quarter. Cetera Investment Advisers now owns 49,215 shares of the company’s stock valued at $1,395,000 after purchasing an additional 8,432 shares during the last quarter. Natixis Advisors LLC raised its holdings in Moderna by 70.7% during the 1st quarter. Natixis Advisors LLC now owns 17,761 shares of the company’s stock valued at $504,000 after buying an additional 7,356 shares during the period. PNC Financial Services Group Inc. boosted its stake in Moderna by 39.7% during the first quarter. PNC Financial Services Group Inc. now owns 37,887 shares of the company’s stock worth $1,074,000 after buying an additional 10,761 shares during the period. ASR Vermogensbeheer N.V. bought a new position in Moderna during the first quarter valued at $614,000. Finally, Charles Schwab Investment Management Inc. raised its stake in shares of Moderna by 12.2% in the first quarter. Charles Schwab Investment Management Inc. now owns 2,629,865 shares of the company’s stock valued at $74,557,000 after acquiring an additional 285,662 shares during the period. 75.33% of the stock is owned by institutional investors.

Moderna Stock Performance

Shares of NASDAQ MRNA opened at $27.70 on Monday. Moderna, Inc. has a 52-week low of $22.28 and a 52-week high of $48.92. The firm has a market capitalization of $10.82 billion, a price-to-earnings ratio of -3.43 and a beta of 1.11. The stock has a 50 day moving average price of $25.86 and a 200 day moving average price of $26.98.

Moderna (NASDAQ:MRNA) last released its quarterly earnings data on Thursday, November 6th. The company reported ($0.51) EPS for the quarter, topping the consensus estimate of ($2.15) by $1.64. Moderna had a negative return on equity of 29.81% and a negative net margin of 139.61%.The company had revenue of $1.02 billion for the quarter, compared to the consensus estimate of $893.29 million. During the same period last year, the business posted $0.03 EPS. Moderna’s quarterly revenue was down 45.4% on a year-over-year basis. Analysts forecast that Moderna, Inc. will post -9.61 earnings per share for the current year.

Wall Street Analyst Weigh In

Several equities analysts recently commented on the stock. Leerink Partners upped their price target on shares of Moderna from $15.00 to $18.00 and gave the company an “underperform” rating in a report on Friday, November 21st. Barclays dropped their target price on Moderna from $31.00 to $25.00 and set an “equal weight” rating for the company in a research report on Friday, November 7th. Needham & Company LLC reiterated a “hold” rating on shares of Moderna in a report on Monday, October 20th. Weiss Ratings restated a “sell (e+)” rating on shares of Moderna in a report on Wednesday, October 8th. Finally, Wolfe Research reaffirmed an “underperform” rating and issued a $17.00 price objective on shares of Moderna in a research report on Thursday, November 20th. Two research analysts have rated the stock with a Buy rating, twelve have given a Hold rating and five have assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Reduce” and a consensus target price of $29.46.

About Moderna

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.